MRK
MRNA
TEM
The lab coat gets longer sleeves
Tempus AI is leaning further into the Moderna-Merck cancer vaccine machine. The company said it expanded its multi-year collaboration around intismeran autogene, also known as V940/mRNA-4157, which is being studied with Keytruda in certain melanoma and other cancers.
For Tempus, this isn’t just a nice logo parade. It’s getting pulled deeper into the infrastructure behind a potential launch — collecting and transferring tumor tissue and blood samples, then handling next-generation sequencing work that helps power the design and manufacturing process.
Why investors care
This is the kind of deal Wall Street loves to squint at and ask, “Cool, but where’s the revenue?” Financial terms weren’t disclosed, which means you’re left with the classic public-company combo platter: strategic upside, vague dollars, and a stock that still needs to prove the story pays.
A few moving pieces matter here:
- Tempus is becoming more embedded in precision-oncology workflows.
- The collaboration depends on regulatory approvals, so this isn’t a guaranteed payday just yet.
- The broader cancer-vaccine narrative around Moderna and Merck keeps getting more real, which could make Tempus look like a useful picks-and-shovels play.
Big picture
Tempus is trying to be the AWS of cancer data, not just the app on top of it. And if these partnerships keep stacking up, investors may start treating TEM less like a flashy AI health stock and more like infrastructure for the next wave of oncology.